Very excited to have The New Yorker cover the #FSHARP program we've been running here at @DARPA! Synthetic blood analog that is shelf-stable and mass manufacturable to deal with all blood shortages whether for warfighters or in the civilian medical world!

https://t.co/41zItaHSpb